CytoMed Therapeutics (NASDAQ: GDTC) plans first-in-human gamma delta T cell trial in Malaysia

Rhea-AI Filing Summary

CytoMed Therapeutics Limited reported that it has signed a Memorandum of Understanding with Universiti Malaya Medical Centre in Malaysia. The parties plan to explore a multi-site, first-in-human Phase I clinical trial of CytoMed’s patented donor-derived gamma delta T cell product candidate.

The proposed trial would focus on cancer patients who have exhausted standard treatment options and would evaluate both the safety and efficacy of using gamma delta T cells sourced from healthy donors. This represents an early clinical step for CytoMed’s off-the-shelf allogeneic cell therapy approach in Malaysia.

Insights

Biotech clinical development analyst

CytoMed moves toward a first-in-human trial via an exploratory MOU.

CytoMed Therapeutics Limited has signed a Memorandum of Understanding with Universiti Malaya Medical Centre to explore a multi-site, first-in-human Phase I trial of its patented donor-derived gamma delta T cell product. The target population is cancer patients who have exhausted standard treatments, and the trial would assess safety and efficacy of cells taken from healthy donors.

This step signals intent to bring the off-the-shelf allogeneic gamma delta T cell platform into human testing, but an MOU is an initial framework rather than a binding trial launch. Actual clinical initiation will depend on subsequent agreements, regulatory clearances, and site readiness in Malaysia.

Future disclosures may clarify when the Phase I trial is formally approved, the specific cancer indications involved, and how many sites participate. These details will determine the pace and scope of CytoMed’s early-stage clinical development for this technology.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On December 8, 2025, CytoMed Therapeutics Limited (the “Company”) issued a press release announcing that it has signed a Memorandum of Understanding with Universiti Malaya Medical Centre in Malaysia to explore the establishment of a multi-site, first-in-human Phase I clinical trial of the Company’s patented donor-derived gamma delta T cell product candidate. The proposed trial is intended for cancer patients who have exhausted standard treatment options and would evaluate the safety and efficacy of using gamma delta T cells obtained from healthy donors.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Press Release dated December 8, 2025 titled: CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
Date: December 8, 2025	By:	/s/ CHOO Chee Kong
		CHOO Chee Kong Director and Chairman

FAQ

What did CytoMed Therapeutics Limited (GDTC) announce in this Form 6-K?

CytoMed Therapeutics Limited announced that it signed a Memorandum of Understanding with Universiti Malaya Medical Centre in Malaysia to explore a multi-site, first-in-human Phase I clinical trial of its patented donor-derived gamma delta T cell product candidate.

What type of clinical trial is CytoMed Therapeutics (GDTC) planning to explore?

The company is planning to explore a multi-site, first-in-human Phase I clinical trial that would evaluate the safety and efficacy of its donor-derived gamma delta T cell product candidate.

Which patients are targeted in CytoMed Therapeutics' proposed trial?

The proposed trial is intended for cancer patients who have exhausted standard treatment options, focusing on those with limited remaining therapeutic choices.

What technology is CytoMed Therapeutics (GDTC) aiming to advance with this collaboration?

CytoMed aims to advance its off-the-shelf donor-derived gamma delta T cells allogeneic technology, using gamma delta T cells obtained from healthy donors to treat cancers in Malaysia.

Who is CytoMed Therapeutics' clinical partner in Malaysia?

CytoMed’s clinical partner in Malaysia under the Memorandum of Understanding is Universiti Malaya Medical Centre, described as a renowned and prestigious hospital partner.

Where can investors find more details about CytoMed Therapeutics' planned Phase I trial?

More details are provided in the press release furnished as Exhibit 99.1, titled "CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia."